Gemfibrozil and its glucoronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 1, 2004, Pages 228-236

  Shitara, Yoshihisa ^a   Hirano, Masaru ^b   Sato, Hitoshi ^a   Sugiyama, Yuichi ^b  

^a SHOWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYTOCHROME P450 2C8; GEMFIBROZIL; GEMFIBROZIL 1 O BETA GLUCURONIDE; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PRAVASTATIN; PROTEIN; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; CARBON; CYP2C8 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; GLUCURONIC ACID; PLASMA PROTEIN; PYRIDINE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; CYTOLOGY; DRUG INTERACTION; LIVER; LIVER CELL; METABOLISM;

ANTILIPEMIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD PROTEINS; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GEMFIBROZIL; GLUCURONATES; HEPATOCYTES; HUMANS; LIVER; ORGANIC ANION TRANSPORT POLYPEPTIDE C; PYRIDINES;

EID: 4644301418     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.068536     Document Type: Article

References (40)

1. Abdul-Ghaffar NU and El-Sonbaty MR (1995) Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrfozil therapy. J Clin Gastroenterol 21:340-341.
2. Backman JT, Kyrklund C, Kivistö KT, Wang J-S, and Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122-129.
3. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
4. Bruno-Joyce J, Dugas JM, and MacCausland OE (2001) Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother 35:1016-1019.
5. Cui Y, König J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
6. Fujino H, Yamada I, Shimada S, Yoneda M, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyl-transferase enzymes involved in lactonization. Xenobiotica 33:27-41.
7. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
8. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab Dispos 31:1108-1116.
9. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, and Iijima H (2003) The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med 19:381-389.
10. Hengy H and Kölle EU (1985) Determination of gemfibrozil in plasma by high performance liquid chromatography. Arzneimittelforschung 35:1637-1639.
11. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther, in press.
12. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
13. König J, Cui Y, Nies AT, and Keppler D (2000a) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol 278:G156-G164.
14. König J, Cui Y, Nies AT, and Keppler D (2000b) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161-23168.
15. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Latila J, and Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340-345.
16. Kyrklund C, Backman JT, Neuvonen M, and Neuvonen PJ (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73:538-544.
17. Mathew P, Cuddy T, Tracewell WG, and Salazar D (2004) An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers (Abstract PI-115). Clin Pharmacol Ther 75:P33.
18. Matzno S, Tazuya-Murayama K, Tanaka H, Yasuda S, Mishima M, Uchida T, Nakabayashi T, and Matsuyama K (2003) Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 55:795-802.
19. Moghadasian MH, Mancini GB, and Frohlich JJ (2000) Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother 1:683-695.
20. Mück W (2000) Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 39:99-116.
21. Nakagawa A, Shigeta A, Iwabuchi H, Horiguchi M, Nakamura K, and Takahagi H (1991) Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system. Biomed Chromatogr 5:68-73.
22. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, and Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867.
23. Okerholm RA, Keeley FJ, Peterson FE, and Glazko AJ (1976) The metabolism of gemfibrozil. Proc R Soc Med 69 (Suppl 2):11-14.
24. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002a) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
25. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, and Lin JH (2002b) Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30:1280-1287.
26. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson G, and Baillie TA (2002c) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
27. Regazzi MB, Campana IC, Raddato V, Lesi C, Perani G, Gavazzi A, and Vigano M (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732-2734.
28. Roca B, Calvo B, and Monferrer R (2002) Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy. Ann Pharmacother 36:730-731.
29. Sabordo L, Sallustio BC, Evans AM, and Nation RL (1999) Hepatic disposition of the acyl glucuronidel-O-gemfibrozil β-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J Pharmacol Exp Ther 288:414-420.
30. Sabordo L, Sallustio BC, Evans AM, and Nation RL (2000) Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-β-D-glucuronide: effects of clofibric acid, acetaminophen and acetaminophen glucuronide. J Pharmacol Exp Ther 295:44-50.
31. Sallustio BC, Fairchild BA, Shanahan K, Evans AM, and Nation RL (1996) Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab Dispos 24:984-989.
32. Sasaki M, Suzuki H, Ito K, Abe T, and Sugiyama Y (2002) Transcellular transport of organic anions across double-transfected MDCKII cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497-6503.
33. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
34. Spence JD, Munoz CE, Hendricks L, Latchinian L, and Khouri HE (1995) Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76:80A-83A.
35. Staffa JA, Chang J, and Green G (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540.
36. Todd PA and Ward A (1988) Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 36:314-339.
37. Ueda K, Kato Y, Komatsu K, and Sugiyama Y (2001) Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 297:1036-1043.
38. Wang J-S, Neuvonen M, Wen X, Backman JT, and Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356.
39. Wen X, Wang J-S, Backman JT, Kivistö KT, and Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361.
40. Wierzbicki AS, Mikhalidis DP, Wray R, Schacter M, Cramb R, Simpson WG, and Byrne CB (2003) Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 19:155-168.